United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

22 Sep 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Vermillion reports Q2 loss per share $0.04
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Vermillion Inc -:Vermillion reports second quarter 2017 results.Q2 loss per share $0.04.Q2 revenue rose 27 percent to $898,000.  Full Article

Vermillion Q1 loss per share $0.05
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Vermillion Inc :Vermillion reports first quarter 2017 results.Q1 loss per share $0.05.Q1 revenue $726,000 versus $505,000.  Full Article

Vermillion files for resale of up to 6.6 mln shares of common stock
Tuesday, 11 Apr 2017 04:18pm EDT 

Vermillion Inc :Files for resale of up to 6.6 million shares of co's common stock - sec filing.  Full Article

Vermillion Q4 loss per share $0.05
Wednesday, 29 Mar 2017 04:01pm EDT 

Vermillion Inc : Vermillion reports fourth quarter and full year 2016 results . Q4 loss per share $0.05 . Q4 revenue $805,000 versus $361,000 . Vermillion Inc- expect cash utilization to decrease further to approximately $2.6 million in q1 of 2017, net of offering proceeds and expenses .Vermillion Inc- as of December 31, 2016, cash and equivalents totaled $5.2 million.  Full Article

Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017
Monday, 13 Mar 2017 04:40pm EDT 

Vermillion Inc : Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017 .Vermillion Inc - primary purpose of amendment was to extend initial term of testing and services agreement from March 11, 2017 to March 11, 2018.  Full Article

Vermillion announces reimbursement code updates for Overa and OVA1
Monday, 9 Jan 2017 09:00am EST 

Vermillion Inc :Vermillion Inc - Co and unit Aspira Labs, have received a proprietary laboratory analyses (PLA) code (0003U) for Overa (MIA2G).  Full Article

Vermillion Q3 revenue $623,000
Thursday, 10 Nov 2016 04:03pm EST 

Vermillion Inc : Vermillion Inc - expect net cash utilization to be less than $3.0 million in Q4 of 2016 . Vermillion reports third quarter 2016 results . Q3 loss per share $0.07 .Q3 revenue $623,000 versus $330,000.  Full Article

Vermillion reports Q2 loss per share $0.07
Wednesday, 10 Aug 2016 07:30am EDT 

Vermillion Inc : Vermillion reports second quarter 2016 results . Q2 loss per share $0.07 .Q2 revenue $709,000 versus $535,000.  Full Article

Vermillion Inc Q1 loss per share $0.09
Monday, 16 May 2016 04:15pm EDT 

Vermillion Inc : Expect net cash utilization of $2.0 million - $3.0 million in q2 of 2016 . Vermillion reports first quarter 2016 results .Q1 loss per share $0.09.  Full Article

Vermillion, Inc announces FDA Clearance of Overa®
Monday, 21 Mar 2016 08:15am EDT 

Vermillion, Inc:Says Receipt of 510(k) marketing clearance from the FDA for successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass.Says Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®.Overa replaces two of the five OVA1 biomarkers with HE4 and FSH in order to improve specificity and reduce the need for physicians to determine menopausal status when interpreting the test.  Full Article

BRIEF-Vermillion reports Q2 loss per share $0.04

* Q2 revenue rose 27 percent to $898,000 Source text for Eikon: Further company coverage: